keyword
MENU ▼
Read by QxMD icon Read
search

Truvada

keyword
https://www.readbyqxmd.com/read/28423992/secrecy-empowerment-and-protection-positioning-prep-in-kwazulu-natal-south-africa
#1
Eliza Govender, Leila Mansoor, Kate MacQueen, Quarraisha Abdool Karim
The release of World Health Organisation guidelines recommending the prophylactic use of daily Truvada(®) for all populations at high risk of acquiring HIV opens the way for implementation of oral pre-exposure prophylaxis (PrEP). The impact of new prevention technologies is, however, dependent on demand creation strategies such as user awareness, acceptability and access, which in turn are influenced by sociocultural and gender norms. This study was conducted in three locations in KwaZulu-Natal, urban, rural and peri-urban, with six participatory workshops...
April 20, 2017: Culture, Health & Sexuality
https://www.readbyqxmd.com/read/28370177/blood-safety-implications-of-donors-using-hiv-pre-exposure-prophylaxis
#2
C R Seed, H Yang, J F Lee
HIV pre-exposure prophylaxis (PrEP) is the use of one or more antiretroviral medications (in combination) to prevent HIV infection. The most commonly used PrEP medication (Truvada(®) , Gilead Sciences, Inc.) acts by inhibiting HIV-1 reverse transcriptase. If someone who is using PrEP unknowingly becomes HIV infected (termed 'PrEP breakthrough infection'), there may be suppressed viral replication resulting in a virus level undetectable by the most sensitive HIV NAT. Failure to seroconvert and seroreversion (loss of previously detectable HIV antibodies) have also both been observed with 2nd, 3rd and 4th generation screening immunoassays, as well as Western blot assays...
March 31, 2017: Vox Sanguinis
https://www.readbyqxmd.com/read/28369381/randomized-controlled-trial-of-the-tolerability-and-completion-of-maraviroc-compared-with-kaletra%C3%A2-in-combination-with-truvada%C3%A2-for-hiv-post-exposure-prophylaxis-mipep-trial
#3
Ana Milinkovic, Paul Benn, Alejandro Arenas-Pinto, Nataliya Brima, Andrew Copas, Amanda Clarke, Martin Fisher, Gabriel Schembri, David Hawkins, Andy Williams, Richard Gilson
Objectives: Post-exposure prophylaxis (PEP) for HIV is often poorly tolerated and not completed. Alternative PEP regimens may improve adherence and completion, aiding HIV prevention. We conducted a randomized controlled trial of a maraviroc-based PEP regimen compared with a standard-of-care regimen using ritonavir-boosted lopinavir. Methods: Patients meeting criteria for PEP were randomized to tenofovir disoproxil/emtricitabine (200/245 mg) once daily plus ritonavir-boosted lopinavir (Kaletra ® 400/100 mg) or maraviroc 300 mg twice daily...
March 20, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28276922/science-technology-power-and-sex-prep-and-hiv-positive-gay-men-in-paris
#4
Julien Brisson, Vinh-Kim Nguyen
The pre-exposure prophylaxis (PrEP) drug Truvada is a new HIV prevention technology that is predominantly promoted as relevant to HIV-negative gay men. This paper explores what PrEP represents for HIV-positive gay men living in Paris, based upon data collected through interviews and ethnographic research. While HIV-positive gay men do not directly consume Truvada through PrEP, they nonetheless hold opinions and understandings of this drug, specifically as it relates to their own sexuality. This paper expands the representations and meanings of this new technology in a different light through the voices of gay men living with HIV in Paris...
February 21, 2017: Culture, Health & Sexuality
https://www.readbyqxmd.com/read/28260694/a-case-study-of-chewed-truvada-%C3%A2-for-prep-maintaining-protective-drug-levels-as-measured-by-a-novel-urine-tenofovir-assay
#5
Linden Lalley-Chareczko, Devon Clark, Athena F Zuppa, Ganesh Moorthy, Caitlin Conyngham, Karam Mounzer, Helen Koenig
FTC/TDF (Truvada®) given as pre-exposure prophylaxis (PrEP) successfully blocks HIV when taken once daily prior to potential HIV exposure. A 22 year old male reported difficulty swallowing FTC/TDF for PrEP and subsequently began chewing the FTC/TDF tablets. Monthly urine samples assessed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) indicated tenofovir levels >1000 ng/mL, indicative of protection from HIV acquisition, over a 48 week period. Data from observational studies of HIV positive patients details the successful treatment of HIV using crushed FTC/TDF delivered via feeding and gastronomy tubes while small, randomized trials of healthy volunteers demonstrate bioequivalence between whole and crushed FTC/TDF...
March 6, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28135199/pre-exposure-prophylaxis-prep-as-an-additional-tool-for-hiv-prevention-among-men-who-have-sex-with-men-in-belgium-the-be-prep-ared-study-protocol
#6
Irith De Baetselier, Thijs Reyniers, Christiana Nöstlinger, Kristien Wouters, Katrien Fransen, Tania Crucitti, Chris Kenyon, Jozefien Buyze, Céline Schurmans, Marie Laga, Bea Vuylsteke
BACKGROUND: Pre-exposure prophylaxis (PrEP) is a promising and effective tool to prevent HIV. With the approval of Truvada as daily PrEP by the European Commission in August 2016, individual European Member states prepare themselves for PrEP implementation following the examples of France and Norway. However, context-specific data to guide optimal implementation is currently lacking. OBJECTIVE: With this demonstration project we evaluate whether daily and event-driven PrEP, provided within a comprehensive prevention package, is a feasible and acceptable additional prevention tool for men who have sex with men (MSM) at high risk of acquiring HIV in Belgium...
January 30, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28130774/pre-exposure-prophylaxis-for-hiv-prevention-safety-concerns
#7
REVIEW
Raymond A Tetteh, Barbara A Yankey, Edmund T Nartey, Margaret Lartey, Hubert G M Leufkens, Alexander N O Dodoo
Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry " http://www...
April 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/27974330/post-exposure-prophylaxis-guidelines-for-children-and-adolescents-potentially-exposed-to-hiv
#8
REVIEW
Alasdair Bamford, Gareth Tudor-Williams, Caroline Foster
UK guidelines for HIV post-exposure prophylaxis (PEP) in adults have recently been updated. Indications for PEP have been modified and there has been a change in the recommended antiretroviral therapy for adults to a combination of raltegravir with tenofovir and emtricitabine (Truvada). Raltegravir and tenofovir are now available in paediatric formulations and offer improved safety and tolerability over previously recommended ritonavir-boosted lopinavir with zidovudine. This guideline provides recommendations for those caring for children potentially exposed to HIV and other bloodborne viruses in primary care, emergency departments, secondary care and specialist paediatric HIV centres...
January 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/27918570/hiv-pre-exposure-prophylaxis-is-it-just-about-pills
#9
Jose V Fernandez-Montero
The increasing use of antiretrovirals for averting HIV infection before potential exposure is under debate. Whereas there is no doubt about the benefit of using Truvada® (tenofovir plus emtricitabine) to reduce HIV acquisition in uninfected persons who have sex with HIV-infected stable partners, concerns are rising about the increasing rate of sexually transmitted infections in subjects engaged in sex with multiple partners, due to misinterpreted self-security.
October 2016: AIDS Reviews
https://www.readbyqxmd.com/read/27800524/slow-cd4-t-cell-recovery-in-human-immunodeficiency-virus-hepatitis-b-virus-coinfected-patients-initiating-truvada-based-combination-antiretroviral-therapy-in-botswana
#10
Motswedi Anderson, Simani Gaseitsiwe, Sikhulile Moyo, Kerapetse P Thami, Terence Mohammed, Ditiro Setlhare, Theresa K Sebunya, Eleanor A Powell, Joseph Makhema, Jason T Blackard, Richard Marlink, Max Essex, Rosemary M Musonda
Background.  Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection has emerged as an important cause of morbidity and mortality. We determined the response to Truvada-based first-line combination antiretroviral therapy (cART) in HIV/HBV-coinfected verus HIV-monoinfected patients in Botswana. Methods.  Hepatitis B virus surface antigen (HBsAg), HBV e antigen (HBeAg), and HBV deoxyribonucleic acid (DNA) load were determined from baseline and follow-up visits in a longitudinal cART cohort of Truvada-based regimen...
September 2016: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/27760684/preventing-hiv-among-adolescents-with-oral-prep-observations-and-challenges-in-the-united-states-and-south-africa
#11
Sybil Hosek, Connie Celum, Craig M Wilson, Bill Kapogiannis, Sinead Delany-Moretlwe, Linda-Gail Bekker
INTRODUCTION: Adolescents and young adults aged <25 are a key population in the HIV epidemic, with very high HIV incidence rates in many geographic settings and a large number who have limited access to prevention services. Thus, any biomedical HIV prevention approach should prepare licensure and implementation strategies for young populations. Oral pre-exposure prophylaxis (PrEP) is the first antiretroviral-based prevention intervention with proven efficacy across many settings and populations, and regulatory and policy approvals at global and national levels are occurring rapidly...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27749110/reactions-and-receptivity-to-framing-hiv-prevention-message-concepts-about-pre-exposure-prophylaxis-for-black-and-latino-men-who-have-sex-with-men-in-three-urban-us-cities
#12
Matthew J Mimiaga, Elizabeth F Closson, Shanice Battle, Jeffrey H Herbst, Damian Denson, Nicole Pitts, Jeremy Holman, Stewart Landers, Gordon Mansergh
Men who have sex with men (MSM) of color are disproportionately affected by HIV in the United States. Pre-exposure prophylaxis (PrEP) using antiretroviral medications is a newer biomedical prevention modality with established efficacy for reducing the risk of acquiring HIV. We conducted formative qualitative research to explore audience reactions and receptivity to message concepts on PrEP as part of the development of prevention messages to promote PrEP awareness among black and Latino MSM in the United States...
October 2016: AIDS Patient Care and STDs
https://www.readbyqxmd.com/read/27704821/discovery-and-development-of-the-anti-human-immunodeficiency-virus-drug-emtricitabine-emtriva-ftc
#13
Dennis C Liotta, George R Painter
The HIV/AIDS epidemic, which was first reported on in 1981, progressed in just 10 years to a disease afflicting 10 million people worldwide including 1 million in the US. In 1987, AZT was approved for treating HIV/AIDS. Unfortunately, its clinical usefullness was severly limited by associated toxicities and the emergence of resistance. Three other drugs that were approved in the early 1990s suffered from similar liabilities. In 1990, the Liotta group at Emory University developed a highly diastereoselective synthesis of racemic 3'-thia-2',3'-dideoxycytidine and 3'-thia-2',3'-5-fluorodideoxycytidine and demonstrated that these compounds exhibited excellent anti-HIV activity with no apparent cytotoxicity...
October 5, 2016: Accounts of Chemical Research
https://www.readbyqxmd.com/read/27632233/an-hiv-preexposure-prophylaxis-demonstration-project-and-safety-study-for-young-msm
#14
Sybil G Hosek, Bret Rudy, Raphael Landovitz, Bill Kapogiannis, George Siberry, Brandy Rutledge, Nancy Liu, Jennifer Brothers, Kathleen Mulligan, Gregory Zimet, Michelle Lally, Kenneth H Mayer, Peter Anderson, Jennifer Kiser, James F Rooney, Craig M Wilson
BACKGROUND: Young men who have sex with men (YMSM) are a key population for implementation of preexposure prophylaxis (PrEP) interventions. This open-label study examined adherence to PrEP and assessed sexual behavior among a diverse sample of YMSM in 12 US cities. METHODS: Eligible participants were 18- to 22-year-old HIV-uninfected MSM who reported HIV transmission risk behavior in the previous 6 months. Participants were provided daily tenofovir disoproxil fumarate/emtricitabine (Truvada)...
January 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27609216/prep-truvada-and-gilead
#15
Andrew Jack
No abstract text is available yet for this article.
September 8, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27295507/prep-on-twitter-information-barriers-and-stigma
#16
Joseph Schwartz, Josh Grimm
On May 14, 2014 the Centers for Disease Control and Prevention (CDC) endorsed the drug Truvada as an HIV preventative, called pre-exposure prophylaxis (PrEP). PrEP has been shown to dramatically reduce the risk of HIV infection, but its rate of adoption has been slow, and discourse surrounding it has been marked by stigma and uncertainty. The purpose of this study was to investigate how PrEP was discussed on Twitter. Our analysis focused on barriers to PrEP adoption and stigmatization of PrEP users. We analyzed a random sample of 1,093 top tweets about PrEP posted to Twitter a year before and a year after the CDC's endorsement...
April 2017: Health Communication
https://www.readbyqxmd.com/read/27093238/when-and-why-women-might-suspend-prep-use-according-to-perceived-seasons-of-risk-implications-for-prep-specific-risk-reduction-counselling
#17
Emily Namey, Kawango Agot, Khatija Ahmed, Jacob Odhiambo, Joseph Skhosana, Greg Guest, Amy Corneli
Oral pre-exposure prophylaxis (PrEP) using the antiretroviral drug emtricitabine/tenofovir disoproxil fumarate (Truvada) has been shown to dramatically reduce the risk of HIV acquisition for women at higher risk of infection if taken daily. Understanding when and why women would intentionally stop using an efficacious oral PrEP drug within the context of their 'normal' daily lives is essential for delivering effective PrEP risk-reduction counselling. As part of a larger study, we conducted 60 qualitative interviews with women at higher risk of HIV in Bondo, Kenya, and Pretoria, South Africa...
September 2016: Culture, Health & Sexuality
https://www.readbyqxmd.com/read/27000145/familiarity-with-and-preferences-for-oral-and-long-acting-injectable-hiv-pre-exposure-prophylaxis-prep-in-a-national-sample-of-gay-and-bisexual-men-in-the-u-s
#18
Jeffrey T Parsons, H Jonathon Rendina, Thomas H F Whitfield, Christian Grov
We sought to determine preferences for oral versus long-acting injectable (LAI) PrEP among gay and bisexual men (GBM). We surveyed a national U.S. sample of 1071 GBM about forms of PrEP. LAI PrEP was found to be acceptable among 43.2 % of men when injected monthly compared with 53.6 % of men when injected every 3 months. When asked to choose between forms of PrEP, 46.0 % preferred LAI, 14.3 % oral, 21.7 % whichever was most effective, 10.1 % had no preference, and 7.8 % would not take PrEP. There were no differences in PrEP preferences by race/ethnicity, income, region of residence, or relationship status...
July 2016: AIDS and Behavior
https://www.readbyqxmd.com/read/26984267/uncertainty-in-online-u-s-news-coverage-of-truvada
#19
Joseph Schwartz, Josh Grimm
The purpose of this study was to analyze the frequency of incidents of uncertainty in online news articles about Truvada, a drug used to prevent HIV infection. Using a coding scheme that synthesized uncertainty research from health disciplines and communication studies, we analyzed 235 articles from the most-read United States-based news websites. Our results showed that 80.4% of articles contained at least one incident of uncertainty, that articles contained significantly more incidents of uncertainty before the Centers for Disease Control and Prevention (CDC) endorsed Truvada compared to after the CDC endorsed the drug, and that articles mentioning men who have sex with men (MSM) contained significantly more incidents of uncertainty than articles in which they were not mentioned...
October 2016: Health Communication
https://www.readbyqxmd.com/read/26906023/reporting-of-adherence-in-the-voice-trial-did-disclosure-of-product-nonuse-increase-at-the-termination-visit
#20
Barbara S Mensch, Elizabeth R Brown, Karen Liu, Jeanne Marrazzo, Zvavahera Mike Chirenje, Kailazarid Gomez, Jeanna Piper, Karen Patterson, Ariane van der Straten
VOICE-a phase 2B, placebo-controlled, randomized trial testing daily use of an antiretroviral tablet (tenofovir or Truvada) or daily use of tenofovir gel in 5029 women from South Africa, Uganda, and Zimbabwe-found none of the drug regimens effective in reducing HIV-1 acquisition in the intent-to-treat analysis. More than half of women assigned to active products in a case cohort sample had no drug detected in any plasma specimens tested during the trial. Yet, in response to questions asked of participants during the trial, ≥90 % of doses were reportedly taken...
November 2016: AIDS and Behavior
keyword
keyword
83063
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"